Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556698 | 1.00 | AKR1C1 (0.38) | AKR1C1OPRK1HTTLMNASMN1; SMN2 | |
| SCHEMBL10751965 | 0.75 | SLC6A4 (0.44) | OPRK1MAPT | |
| SCHEMBL28257086 | 0.73 | KDM1A (0.44) | AKR1C1OPRK1MAOBDPP4 | |
| SCHEMBL11248709 | 0.69 | HSD11B1 (0.45) | AKR1C1HTTLMNAHDAC4 | |
| SCHEMBL10743036 | 0.67 | SIGMAR1 (0.42) | HTTLMNASMN1; SMN2 | |
| SCHEMBL10691957 | 0.67 | CHRNB2 (0.41) | OPRK1 | |
| SCHEMBL11086077 | 0.67 | OPRK1 (0.55) | OPRK1MAOBGAA | |
| SCHEMBL9950472 | 0.67 | OPRK1 (0.55) | OPRK1MAOBGAA | |
| SCHEMBL2119239 | 0.67 | OPRK1 (0.55) | OPRK1MAOBGAA | |
| SCHEMBL11244360 | 0.66 | LMNA (0.41) | AKR1C1HTTLMNASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246797-B1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |